United StatesÚltimas notícias

Biopharmaceutical firm Nuvectis (NASDAQ:NVCT) licensed exclusive ex-China rights for two clinical drug assets in a deal valued up to $1.461 billion.

US Vice President JD Vance says a good foundation has been laid to end the war with Iran, but more work needs to be done. He spoke to reporters in Switzerland on Monday morning. Bloomberg's Tyler Kendall reports.

Biotechnology firm bioAffinity Technologies (NASDAQ:BIAF) announced preclinical findings showing its novel small interfering RNA therapeutic approach selectively destroys cells from two common skin cancers that affect an estimated 5.4 million annual United States cases.

Booz Allen Hamilton (NYSE:BAH) executed a definitive agreement to acquire Ultra I&C Mission Solutions for $720 million to expand its defense technology portfolio.

Lori Calvasina, head of US equity strategy research at RBC Capital Markets, says the strength of US corporate earnings is propping up stocks amid concern that the Federal Reserve will raise interest rates. But there are limits to how many hikes the market can withstand, she says on Bloomberg Television's ``Surveillance.''

Worksport (NASDAQ:WKSP) announced a preliminary gross margin of approximately 35% for the month of May 2026.

Outdoor Holding Company (NASDAQ:POWW) reported a 10.1% increase in fourth-quarter revenue to $13.9 million.

Alan Greenspan has died at the age of 100. He served as Fed chief for 18 years, from 1987 to 2006, and was credited with guiding a record US economic expansion, but his legacy was later dimmed by the financial crisis that erupted in 2008. Greenspan died on June 22 at his home due to complications of Parkinson's disease. Bloomberg's David Westin looks back at his accomplishments.

Palvella Therapeutics (NASDAQ:PVLA) announced that the FDA granted rolling review for its rare genetic disease drug application.

Organon (NYSE:OGN) finalized a global licensing agreement with Sebela Pharmaceuticals for a hormone-free birth control device that is 99% effective.

REGENXBIO (NASDAQ:RGNX) aligned with the FDA to resubmit its rare disease drug application in Q3 2026.

MapLight (NASDAQ:MPLT) announced that its Phase 2 autism trial of 161 patients missed its primary efficacy endpoint.